drugset / Trial / NCT00672061

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

NCT00672061

Phase 2 Completed 26 enrolled Takeda
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety of ramelteon, once daily (QD), in individuals with obstructive sleep apnea.

Timeline

Start
2003-07
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 16 mg Oral